Search tips
Search criteria 


Logo of bmjcredLink to Publisher's site
Br Med J (Clin Res Ed). 1983 October 15; 287(6399): 1102–1104.
PMCID: PMC1549364

Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.


Uncontrolled studies have suggested that sulphasalazine may be an effective second line agent in rheumatoid arthritis. Sulphasalazine was therefore compared with placebo and intramuscular sodium aurothiomalate in 90 patients with active rheumatoid arthritis. After six months' treatment both sulphasalazine and sodium aurothiomalate had produced significant clinical and laboratory benefit, whereas placebo had produced no significant change in any variable. Thirteen patients stopped taking the placebo because of lack of effect whereas only two patients stopped taking sulphasalazine and one sodium aurothiomalate for this reason. The major toxicity encountered in the group treated with sulphasalazine was nausea or vomiting, or both; this may be related to slow acetylator phenotype. Sulphasalazine appears to be an effective second line agent, and further pharmacokinetic studies might prove useful in diminishing gastrointestinal side effects.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (680K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • KUZELL WC, GARDNER GM. Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis. Calif Med. 1950 Dec;73(6):476–480. [PMC free article] [PubMed]
  • Sinclair RJ, Duthie JJ. Salazopyrin in the Treatment of Rheumatoid Arthritis. Ann Rheum Dis. 1949 Sep;8(3):226–231. [PMC free article] [PubMed]
  • McConkey B, Amos RS, Durham S, Forster PJ, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J. 1980 Feb 16;280(6212):442–444. [PMC free article] [PubMed]
  • McConkey B, Amos RS, Butler EP, Crockson RA, Crockson AP, Walsh L. Salazopyrin in rheumatoid arthritis. Agents Actions. 1978 Jun;8(4):438–441. [PubMed]
  • Bird HA, Dixon JS, Pickup ME, Rhind VM, Lowe JR, Lee MR, Wright V. A biochemical assessment of sulphasalazine in rheumatoid arthritis. J Rheumatol. 1982 Jan-Feb;9(1):36–45. [PubMed]
  • 1958 REVISION of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum. 1959 Feb;2(1):16–20. [PubMed]
  • Schröder H. Simplified method for determining acetylator phenotype. Br Med J. 1972 Aug 26;3(5825):506–507. [PMC free article] [PubMed]
  • EVANS DA, WHITE TA. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed]
  • Mallya RK, Mace BE. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil. 1981 Feb 1;20(1):14–17. [PubMed]
  • Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. [PMC free article] [PubMed]
  • Azad Khan AK, Nurazzaman M, Truelove SC. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. J Med Genet. 1983 Feb;20(1):30–36. [PMC free article] [PubMed]
  • Schröder H, Evans DA. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972 Apr;13(4):278–284. [PMC free article] [PubMed]

Articles from British Medical Journal (Clinical Research Ed.) are provided here courtesy of BMJ Publishing Group